je.st
news
Tag: merck
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab
2014-09-17 14:30:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J., and MUMBAI, India WHITEHOUSE STATION, N.J., and MUMBAI, India--(BUSINESS WIRE)--Merck & Co., Inc., (NYSE:MRK), known as MSD outside the United States and Canada, and Sun Pharmaceutical Industries Ltd. Language: English Contact: MerckMedia:Ian McConnell, 908- 423-3046Investor:Justin Holko, 908-423-5088orSun PharmaMedia:Frederick Castro, +91-22-66455964Investor:Nimish Desai, +91-22-66455717 Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: 524715 Exchange: MUMBAI read more
Michigan Vet Students Earn Merck Scholarships
2014-09-16 16:51:27| Beef
Three veterinary students at Michigan State University who are preparing for a career as food animal practitioners got a big boost in helping to pay for their education, courtesy of Merck Animal Health and the Food Systems Fellowship Program coordinated by the Michigan State University College of Veterinary Medicine. read more
Tags: students
michigan
earn
vet
Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis
2014-09-15 19:30:00| Merck.com - Product News
Dateline City: WHITEHOUSE STATION, N.J. Merck now expects to submit the New Drug Application for odanacatib with the U.S. Food and Drug Administration (FDA) in 2015 WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced data from the pivotal Phase 3 fracture outcomes study for odanacatib in postmenopausal women with osteoporosis. Odanacatib is Mercks investigational once-weekly cathepsin K inhibitor. In the Long-Term Odanacatib Fracture Trial (LOFT), odanacatib met its primary endpoints and significantly reduced the risk of osteoporotic hip, spine and non-vertebral fractures compared with placebo. Language: English Contact: MerckMedia:Pam Eisele, 267-305-3558Tracy Ogden, 215-370-5597orInvestors:Justin Holko, 609-915-8293 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: for
data
study
treatment
Merck Animal Health Introduces New Vaccine to Protect against Porcine Reproductive and Respiratory Syndrome
2014-09-10 02:00:00| ThePigSite - Industry News
US - Merck Animal Health today announced the introduction of PRIME PAC™ PRRS+, a vaccine for reducing clinical signs of reproductive disease in female breeding-age swine and respiratory disease in pigs three to four weeks of age and older due to porcine reproductive and respiratory syndrome virus (PRRSv).
Tags: health
animal
protect
syndrome
Merck Animal Health Introduces New Vaccine to Protect against PRRS
2014-09-09 21:02:00| National Hog Farmer
Source: Merck Animal Health On Sept. 9 Merck Animal Health announced the introduction of Prime Pac PRRS+, a vaccine for reducing clinical signs of reproductive disease in female breeding-age swine and respiratory disease in pigs three to four weeks of age and older due to porcine reproductive and respiratory syndrome virus. read more
Tags: health
animal
protect
introduces
Sites : [71] [72] [73] [74] [75] [76] [77] [78] [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] next »